BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA
暂无分享,去创建一个
E. Parovichnikova | O. Gavrilina | S. Bondarenko | I. Galtseva | A. Sokolov | V. Troitskaya | V. Savchenko | N. M. Kapranov | L. Kuzmina | S. Kulikov | I. Lukyanova | T. I. Lobanova | E. Usikova | K. Zarubina | Julia O. Davidova